PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

Table 4 Association between PPARγ2 CG/GG genotype (Ala variant) and serum adipokines in HIV/HCV coinfected patients

	CC	CG/GG	p-value^(a)	aAMR (95% CI)	p-value^(b)
HGF (pg/mL)	1964.9 (2079.2)	1044.4 (1327.1)	0.003	0.61 (0.39; 0.94)	0.028
NGF (pg/mL)	9.48 (9.43)	6.16 (8.32)	0.008	0.47 (0.26; 0.84)	0.010
PAI-1 (pg/mL)	1474.9 (17338.2)	1363.1 (7366.9)	0.721	0.783(0.36; 1.69)	0.534
Leptin (pg/mL)	3438.1 (154050.1)	5547.6 (22928.2)	0.529	0.93 (0.55; 1.58)	0.795
Resistin (pg/mL)	1233.1 (15063.9)	1070.4 (2795.7)	0.478	0.76 (0.39; 1.47)	0.425
Adiponectin (ng/mL)	662.9 (10917.3)	1226.6 (4993.1)	0.634	1.14 (0.39; 3.31)	0.800

Values expressed as median [interquartile range = upper quartile (Q3) - lower quartile (Q1)] and adjusted arithmetic mean ratio (aAMR) [95% of confidence interval (95% CI)]. Statistically significant differences are shown in bold. ^(a)P-values were calculated by generalized linear models (GLM) with gamma distribution (log-link). ^(b)P-values were calculated by GLM with log-link adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section).
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, HGF hepatic growth factor, NGF nerve growth factor, PAI-1 plasminogen activator inhibitor-1.

ISSN: 1479-5876